12 Parathyroid hormone and vitamin D receptors

Allen M. Spiegel, Stephen J. Marx

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Parathyroid hormone (PTH), an 84-amino-acid polypeptide hormone, interacts with plasma membrane-bound receptors on bone and kidney cells, thereby increasing intracellular cAMP. Although the synthetic amino terminal 1-34 fragment of PTH possesses full biological activity, there is no firm evidence that hormone cleavage is a requisite step in the biological action of PTH. In contrast, vitamin D must undergo hydroxylations in the 1 and 25 positions in order to become fully active on target organs. 1,25(OH)2D, a steroid-like hormone, interacts with cytoplasmic receptors in small intestinal and bone cells. The 1,25(OH)2D-receptor complex (in the same manner as other steroid hormones) directs the synthesis of specific proteins. The integrated actions of PTH and vitamin D maintain serum calcium within narrow limits, thereby permitting normal neuromuscular and secretory function, as well as normal bone mineralization. Abnormalities in hormone secretion (PTH) or metabolic activation (vitamin D) lead to clinical disturbances in hormone action. Abnormalities at the level of the receptor-effector system for PTH and vitamin D also lead to clinical disturbances characterized by resistance to hormone action. Specific examples of the latter include pseudohypoparathyroidism, in which deficient activity of a component (the G unit) of the adenylate cyclase complex may lead to resistance to PTH, and hereditary vitamin D-dependent rickets type II, in which abnormalities in the nuclear uptake of 1,25(OH)2D may lead to impaired response to 1,25(OH)2D.

Original languageEnglish (US)
Pages (from-to)221-241
Number of pages21
JournalClinics in Endocrinology and Metabolism
Volume12
Issue number1
DOIs
StatePublished - 1983
Externally publishedYes

Fingerprint

Calcitriol Receptors
Parathyroid Hormone
Vitamin D
Hormones
Bone
Steroid hormones
Steroids
Pseudohypoparathyroidism
Bone and Bones
Physiologic Calcification
Hydroxylation
Rickets
Peptide Hormones
Cell membranes
Cytoplasmic and Nuclear Receptors
Bioactivity
Adenylyl Cyclases
Chemical activation
Cell Membrane
Calcium

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

12 Parathyroid hormone and vitamin D receptors. / Spiegel, Allen M.; Marx, Stephen J.

In: Clinics in Endocrinology and Metabolism, Vol. 12, No. 1, 1983, p. 221-241.

Research output: Contribution to journalArticle

@article{e9501af6463544ceb191c7abb1f4bd42,
title = "12 Parathyroid hormone and vitamin D receptors",
abstract = "Parathyroid hormone (PTH), an 84-amino-acid polypeptide hormone, interacts with plasma membrane-bound receptors on bone and kidney cells, thereby increasing intracellular cAMP. Although the synthetic amino terminal 1-34 fragment of PTH possesses full biological activity, there is no firm evidence that hormone cleavage is a requisite step in the biological action of PTH. In contrast, vitamin D must undergo hydroxylations in the 1 and 25 positions in order to become fully active on target organs. 1,25(OH)2D, a steroid-like hormone, interacts with cytoplasmic receptors in small intestinal and bone cells. The 1,25(OH)2D-receptor complex (in the same manner as other steroid hormones) directs the synthesis of specific proteins. The integrated actions of PTH and vitamin D maintain serum calcium within narrow limits, thereby permitting normal neuromuscular and secretory function, as well as normal bone mineralization. Abnormalities in hormone secretion (PTH) or metabolic activation (vitamin D) lead to clinical disturbances in hormone action. Abnormalities at the level of the receptor-effector system for PTH and vitamin D also lead to clinical disturbances characterized by resistance to hormone action. Specific examples of the latter include pseudohypoparathyroidism, in which deficient activity of a component (the G unit) of the adenylate cyclase complex may lead to resistance to PTH, and hereditary vitamin D-dependent rickets type II, in which abnormalities in the nuclear uptake of 1,25(OH)2D may lead to impaired response to 1,25(OH)2D.",
author = "Spiegel, {Allen M.} and Marx, {Stephen J.}",
year = "1983",
doi = "10.1016/S0300-595X(83)80037-1",
language = "English (US)",
volume = "12",
pages = "221--241",
journal = "Clinics in Endocrinology and Metabolism",
issn = "0300-595X",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - 12 Parathyroid hormone and vitamin D receptors

AU - Spiegel, Allen M.

AU - Marx, Stephen J.

PY - 1983

Y1 - 1983

N2 - Parathyroid hormone (PTH), an 84-amino-acid polypeptide hormone, interacts with plasma membrane-bound receptors on bone and kidney cells, thereby increasing intracellular cAMP. Although the synthetic amino terminal 1-34 fragment of PTH possesses full biological activity, there is no firm evidence that hormone cleavage is a requisite step in the biological action of PTH. In contrast, vitamin D must undergo hydroxylations in the 1 and 25 positions in order to become fully active on target organs. 1,25(OH)2D, a steroid-like hormone, interacts with cytoplasmic receptors in small intestinal and bone cells. The 1,25(OH)2D-receptor complex (in the same manner as other steroid hormones) directs the synthesis of specific proteins. The integrated actions of PTH and vitamin D maintain serum calcium within narrow limits, thereby permitting normal neuromuscular and secretory function, as well as normal bone mineralization. Abnormalities in hormone secretion (PTH) or metabolic activation (vitamin D) lead to clinical disturbances in hormone action. Abnormalities at the level of the receptor-effector system for PTH and vitamin D also lead to clinical disturbances characterized by resistance to hormone action. Specific examples of the latter include pseudohypoparathyroidism, in which deficient activity of a component (the G unit) of the adenylate cyclase complex may lead to resistance to PTH, and hereditary vitamin D-dependent rickets type II, in which abnormalities in the nuclear uptake of 1,25(OH)2D may lead to impaired response to 1,25(OH)2D.

AB - Parathyroid hormone (PTH), an 84-amino-acid polypeptide hormone, interacts with plasma membrane-bound receptors on bone and kidney cells, thereby increasing intracellular cAMP. Although the synthetic amino terminal 1-34 fragment of PTH possesses full biological activity, there is no firm evidence that hormone cleavage is a requisite step in the biological action of PTH. In contrast, vitamin D must undergo hydroxylations in the 1 and 25 positions in order to become fully active on target organs. 1,25(OH)2D, a steroid-like hormone, interacts with cytoplasmic receptors in small intestinal and bone cells. The 1,25(OH)2D-receptor complex (in the same manner as other steroid hormones) directs the synthesis of specific proteins. The integrated actions of PTH and vitamin D maintain serum calcium within narrow limits, thereby permitting normal neuromuscular and secretory function, as well as normal bone mineralization. Abnormalities in hormone secretion (PTH) or metabolic activation (vitamin D) lead to clinical disturbances in hormone action. Abnormalities at the level of the receptor-effector system for PTH and vitamin D also lead to clinical disturbances characterized by resistance to hormone action. Specific examples of the latter include pseudohypoparathyroidism, in which deficient activity of a component (the G unit) of the adenylate cyclase complex may lead to resistance to PTH, and hereditary vitamin D-dependent rickets type II, in which abnormalities in the nuclear uptake of 1,25(OH)2D may lead to impaired response to 1,25(OH)2D.

UR - http://www.scopus.com/inward/record.url?scp=0020961819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020961819&partnerID=8YFLogxK

U2 - 10.1016/S0300-595X(83)80037-1

DO - 10.1016/S0300-595X(83)80037-1

M3 - Article

C2 - 6303646

AN - SCOPUS:0020961819

VL - 12

SP - 221

EP - 241

JO - Clinics in Endocrinology and Metabolism

JF - Clinics in Endocrinology and Metabolism

SN - 0300-595X

IS - 1

ER -